Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Feature Papers in the Section “Cancer Therapy” in 2025
share announcement

Feature Papers in the Section “Cancer Therapy” in 2025

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 498

Special Issue Editors

Dr. Abdullah Esmail

E-Mail Website
Guest Editor
1. Section of Gastrointestinal Oncology—Houston Methodist Neal Cancer Center and Institute of Academic Medicine, 6445 Fannin, OPC-24, Houston, TX 77030, USA
2. Houston Methodist Research Institute, Houston, TX 77030, USA
Interests: transplant oncology; liver cancer; cholangiocarcinoma; targeted therapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Dr. Qiang Wang

E-Mail Website
Guest Editor
1. Instructor of Cancer Biology in Medicine, Houston Methodist, Academic and Research Institute, Houston, TX 77030, USA
2. Dr. Mary and Ron Neal Cancer Center, Houston Methodist, Houston, TX 77030, USA
Interests: cancer biology; solid cancers; hem-oncology; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Hiroyuki Takei

E-Mail Website
Guest Editor
Department of Breast Surgery and Oncology, Nippon Medical School, Bunkyo City, Tokyo 113-8602, Japan
Interests: breast cancer; endocrine therapy; chemotherapy; surgical therapy; tumor angiogenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of the Special Issue “Feature Paper in Section “Cancer Therapy” in 2024” (https://www.mdpi.com/journal/cancers/special_issues/851NXE23AN).

As a result of the development and improvement of modalities for systematic and localized treatment, the field of oncology has undergone a complete revolution. To effectively manage the progression of cancer, it is essential to have therapeutic approaches that are both precise and targeted, as well as those that are particular to the affected area and may be utilized at an early stage. The major method that is utilized for people who are qualified to undergo surgical removal of their tumor is one of these. Chemotherapy is a medication that is frequently used in the treatment of cancer, yet it is notorious for the significant toxicity that it causes in patients. On the other hand, as a pharmaceutical intervention, it is currently being utilized in conjunction with immunotherapy increasingly frequently. The effectiveness of immunotherapy is based on its capacity to strengthen the immune system of the host, which makes it an appropriate supplement to the standard of care that has been established for long-term treatment. In addition, immunotherapy has undergone substantial changes, particularly since the Food and Drug Administration (FDA) authorized it for the treatment of more advanced cancers. Additionally, the increasing validity and effectiveness of immunotherapies have been demonstrated in recent clinical research trials, which have been conducted all over the world with the purpose of improving oncology treatments. To improve both survival rates and quality of life in the field of cancer, it is essential to continue developing each of these therapy techniques. This Special Issue will discuss the innovations recently made in chemo- and immunotherapy and other developments and specializations in the field, such as targeted therapy.

Dr. Abdullah Esmail
Dr. Qiang Wang
Prof. Dr. Hiroyuki Takei
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemotherapy
  • immunotherapy for cancer
  • oncology
  • systemic treatment and targeted therapy.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 1243 KiB  
Article
Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study
by Chris W. Govaerts, Miranda C. A. Kramer, Ingeborg Bosma, Frank A. E. Kruyt, Frederike Bensch, J. Marc C. van Dijk, Mathilde Jalving and Anouk van der Hoorn
Cancers 2025, 17(15), 2425; https://doi.org/10.3390/cancers17152425 - 22 Jul 2025
Viewed by 236
Abstract
Background: Pseudoprogression is known to occur after immune-checkpoint inhibitor (ICI) therapy in brain metastasis and can complicate clinical decision-making. Still, its incidence, timing, and clinical presentation remain unclear. A retrospective cohort study in melanoma and non-small cell lung cancer brain metastasis patients was [...] Read more.
Background: Pseudoprogression is known to occur after immune-checkpoint inhibitor (ICI) therapy in brain metastasis and can complicate clinical decision-making. Still, its incidence, timing, and clinical presentation remain unclear. A retrospective cohort study in melanoma and non-small cell lung cancer brain metastasis patients was conducted to address this. Materials and Methods: Brain metastasis patients showing progression on MRI according to response assessment in neuro-oncology brain metastases criteria after starting ICI therapy were included, irrespective of prior irradiation. Lesions were classified as tumour progression (TP) or pseudoprogression based on three-month radiological follow-up or histopathology. TP was assigned if progression was again shown at three months. Pseudoprogression was assigned if lesions showed stability, partial, or complete response at three months. ‘Non-classified’ lesions were those with new or changed treatment during follow-up. Results: A cohort of 98 patients with 233 lesions was included over a 13-year period; 170 lesions were considered non-classified, and 41 and 22 lesions were classified as TP and pseudoprogression respectively. This resulted in a lesion- and patient-specific incidence for pseudoprogression of 9.4% and 17.3% respectively. Due to the large number of lesions that could not be classified, as is the case in clinical practice, the reported incidence in this study is likely an underestimation and can be seen as a ‘minimum’ incidence rate. Ten pseudoprogression (45.5%) and 13 (31.7%) TP lesions were previously irradiated. Pseudoprogression occurred at a median of 2.7 months after starting ICI therapy. The only clinical feature distinguishing patients with TP from pseudoprogression was that TP patients were more likely to need dexamethasone for neurological symptoms. Conclusions: Pseudoprogression has a lesion-specific incidence rate of at least 9.4% and occurs at a median of 2.7 months after starting ICI therapy. Severe neurological symptoms requiring dexamethasone may be a clinical feature typical for TP. Full article
(This article belongs to the Special Issue Feature Papers in the Section “Cancer Therapy” in 2025)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop